• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LivaNova PLC filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/12/24 4:12:18 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email
    livn-20240611
    LIVANOVA PLC0001639691false00016396912024-06-112024-06-11

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 11, 2024

    livanova8ktemplat_image.jpg
    LivaNova PLC
    (Exact Name of Registrant as Specified in its Charter)
    England and Wales001-3759998-1268150
    (State or Other Jurisdiction
     of Incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

    20 Eastbourne Terrace
    London, W2 6LG
    United Kingdom
    (Address of Principal Executive Offices)

    +44 20 33250660
    (Registrant’s Telephone Number, Including Area Code)

    N/A
    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name on each exchange on which registered
    Ordinary Shares - £1.00 par value per shareLIVNThe NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
    ☐



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    LivaNova PLC (the “Company”) held its 2024 Annual General Meeting of shareholders (the “AGM”) on June 11, 2024. At the AGM, the Company’s shareholders approved Amendment No. 1 (the “A&R 2022 Plan Amendment”) to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the “A&R 2022 Plan”) and Amendment No. 2 (the “2015 Plan Amendment”) to the LivaNova 2015 Incentive Award Plan (the “2015 Plan”). Both the A&R 2022 Plan Amendment and the 2015 Plan Amendment were previously approved by the Company’s Board of Directors (the “Board”) on April 17, 2024, subject to shareholder approval.

    The A&R 2022 Plan Amendment increases the aggregate number of ordinary shares that can be issued under the A&R 2022 Plan pursuant to options or SARs from 2,250,000 to 2,950,000 and the number of ordinary shares that can be issued pursuant to awards other than options or SARs from 1,500,000 to 2,000,000. The other terms of the A&R 2022 Plan, including its expiration date, remain unchanged by the A&R 2022 Plan Amendment.

    The 2015 Plan Amendment increases the aggregate number of shares that can be issued to non-employee directors under the 2015 Plan from 50,000 to 150,000 and extends the expiration date of the 2015 Plan to April 17th, 2034, corresponding to the 10th anniversary of the date the 2015 Plan Amendment was approved by the Board. The other terms of the 2015 Plan remain unchanged by the 2015 Plan Amendment.

    The material terms of the A&R 2022 Plan Amendment and the 2015 Plan Amendment are described in the Company’s definitive Proxy Statement, dated April 26, 2024 (the “2024 Proxy Statement”), under the heading “Proposal 4 — Approval of Amendment No. 1 to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan” and “Proposal 5 — Approval of Amendment No. 2 to the LivaNova PLC 2015 Incentive Award Plan”, which descriptions are incorporated herein by reference. The descriptions of the A&R 2022 Plan Amendment and the 2015 Plan Amendment contained herein and in the 2024 Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the A&R 2022 Plan Amendment and the 2015 Plan Amendment, copies of which are filed respectively hereto as Exhibits 10.1 and 10.2 and are incorporated by reference herein.

    Item 5.07 Submission of Matters to a Vote of Security Holders

    A total of 48,029,376 of the Company’s ordinary shares, representing approximately 88.70% of the shares outstanding and eligible to vote and constituting a quorum, were represented virtually or by proxy at the AGM.

    At the AGM, LivaNova’s shareholders considered 12 proposals as more fully described in the 2024 Proxy Statement, as supplemented on June 6, 2024 and as summarized below. Each of the resolutions 1-11 was adopted and a plurality of votes cast were voted in favor of holding future U.S. Say-on-Pay votes annually with respect to resolution 12. The number of votes for and against, as well as the number of abstentions and broker non-votes are set forth below.

    1. Ordinary resolution to elect, by separate resolutions, each of the following nine (9) directors for a term expiring at the AGM to be held in 2025:

    Mr. J. Christopher Barry

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    45,270,146132,27720,4072,606,546

    Mr. Francesco Bianchi

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    44,852,064557,07913,6872,606,546

    2


    Ms. Stacy Enxing Seng

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    44,760,431648,53713,8622,606,546

    Mr. William A. Kozy

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    45,120,873288,11513,8422,606,546

    Mr. Vladimir Makatsaria

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    45,271,743137,26013,8272,606,546

    Dr. Sharon O'Kane

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    44,918,069491,07413,6872,606,546

    Mr. Todd Schermerhorn

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    45,200,755208,21313,8622,606,546

    Ms. Brooke Story
    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    45,016,151392,81713,8622,606,546

    Mr. Peter Wilver

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    44,875,477533,57913,6872,606,633

    2.    Ordinary resolution to approve, on an advisory basis, the Company’s compensation of its named executive officers (“US Say-on-Pay”).

    3


    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    43,234,3622,174,13814,3302,606,546

    3.    Ordinary resolution to ratify the appointment of PricewaterhouseCoopers LLP, a Delaware limited liability partnership (“PwC-US”), as the Company’s independent registered public accounting firm for 2024.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    47,988,75621,62318,997—

    4.    Ordinary resolution to approve Amendment No. 1 to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    44,675,024733,45214,3542,606,546

    5.     Ordinary resolution to approve Amendment No. 2 to the LivaNova PLC 2015 Incentive Award Plan.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    44,739,690680,4622,6782,606,546

    6. Ordinary resolution to generally and unconditionally authorize the directors, for purposes of section 551 of the Companies Act 2006 (the “Companies Act”) to exercise all powers of the Company to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company up to an aggregate nominal amount of £10,830,212, provided that:

    (A)     (unless previously revoked, varied or renewed by the Company) this authority will expire at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which this resolution is passed, save that the directors may, before this authority expires, make offers or agreements which would or might require shares in the Company to be allotted, or rights to subscribe for, or convert securities into, shares to be granted, after its expiry and the directors may allot shares or grant rights to subscribe for, or convert securities into, shares pursuant to such offers or agreements as if this authority had not expired, and

    (B)     this authority replaces all subsisting authorities previously granted to the directors for the purposes of section 551 of the Companies Act which, to the extent unused at the date of this resolution, are revoked with immediate effect without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made under such authorities.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    47,268,486757,2403,650—

    7. Special Resolution subject to the passing of resolution 6 and in accordance with sections 570 and 573 of the Companies Act, to empower the directors generally to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 6, and/or to sell ordinary shares (as
    4


    defined in section 560 of the Companies Act) held by the Company as treasury shares for cash, in each case as if section 561 of the Companies Act (existing shareholders’ pre-emption rights) did not apply to any such allotment or sale, provided that this power is limited to the allotment of equity securities or sale of treasury shares for cash up to an aggregate nominal amount of £10,830,212, provided that:

    (A)     (unless previously revoked, varied or renewed by the Company) this power will expire at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which this resolution is passed, save that the directors may, before this power expires, make offers or agreements which would or might require equity securities to be allotted and/or treasury shares to be sold after its expiry and the directors may allot equity securities and/or sell treasury shares pursuant to such offers or agreement as if this power had not expired; and

    (B)     this power replaces (except for any power conferred by resolution 6) all subsisting powers previously granted to the directors for the purposes of section 570 of the Companies Act which, to the extent unused at the date of this resolution, are revoked with immediate effect, without prejudice to any allotment of equity securities already made, offered or agreed to be made under such powers.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    45,487,4922,539,0432,841—

    8.    Ordinary resolution to approve, on an advisory basis, the United Kingdom (“UK”) directors’ remuneration report in the form set out in the Company’s UK annual report for the period ended December 31, 2023.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    43,282,6742,121,40418,7522,606,546

    9.    Ordinary resolution to receive and adopt the Company’s audited UK statutory accounts for the year ended December 31, 2023, together with the reports of the directors and auditors thereon.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    45,278,84510,551133,4342,606,546

    10.     Ordinary resolution to re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England (“PwC-UK”), as the Company’s UK statutory auditor for 2024.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    47,988,28222,31618,778—

    11.    Ordinary resolution to authorize the directors and/or the Audit and Compliance Committee to determine the remuneration of the Company’s UK statutory auditor.

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    47,985,46427,68916,223—



    5


    12. Ordinary resolution to approve, on an advisory basis, the frequency of US Say-on-Pay votes (“US Say-on-Frequency”).

    1 Year2 Years3 YearsVotes AbstainedBroker Non-Votes
    22,170,368—252,2555,137,74120,469,012

    Based on the voting results for Proposal 12 at the AGM, and the Board’s consideration of the appropriate voting frequency for the Company at this time, the Board has decided that the Company will include a U.S. Say-on-Pay vote in its proxy materials every year until such time as the next advisory vote is submitted to shareholders regarding the frequency of advisory votes on executive compensation, or until the Board otherwise determines that it is in the best interest of the Company to hold a U.S. Say-on-Pay vote with a different frequency.

    Item 9.01 Financial Statements and Exhibits

    (d)    Exhibits.

    ExhibitDescription
    10.1
    Amendment No. 1 to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan
    10.2
    Amendment No. 2 to the LivaNova PLC 2015 Incentive Award Plan
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)

    6


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    LivaNova PLC
    Date: June 12, 2024
    By: /s/ Michael Hutchinson
    Name: Michael Hutchinson
    Title: SVP, Company Secretary & Chief Legal Officer

    7
    Get the next $LIVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    12/19/2025$81.00Overweight
    KeyBanc Capital Markets
    10/1/2025$55.00Buy → Neutral
    Goldman
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    More analyst ratings

    $LIVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on LivaNova with a new price target

    KeyBanc Capital Markets initiated coverage of LivaNova with a rating of Overweight and set a new price target of $81.00

    12/19/25 8:50:10 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova downgraded by Goldman with a new price target

    Goldman downgraded LivaNova from Buy to Neutral and set a new price target of $55.00

    10/1/25 8:42:07 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded LivaNova from Peer Perform to Outperform and set a new price target of $60.00

    5/20/25 8:01:26 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac

    3/27/26 10:15:00 AM ET
    $CLOV
    $LIVN
    $MBOT
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Biological Products (No Diagnostic Substances)

    LivaNova to Announce First-Quarter 2026 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 946097. A replay will be available on the

    3/25/26 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

    – First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language – Next-generation, MRI-compatible device expected to launch in the first half of 2027, pending FDA supplement review LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with an

    3/19/26 8:30:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, Cardiopulmonary Poletti Franco exercised 2,140 units of Ordinary Shares at a strike of $57.60 and covered exercise/tax liability with 2,049 units of Ordinary Shares, increasing direct ownership by 1% to 8,941 units (SEC Form 4)

    4 - LivaNova PLC (0001639691) (Issuer)

    3/13/26 5:25:31 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President, Cardiopulmonary Poletti Franco converted options into 967 units of Ordinary Shares and covered exercise/tax liability with 416 units of Ordinary Shares, increasing direct ownership by 7% to 8,850 units (SEC Form 4)

    4 - LivaNova PLC (0001639691) (Issuer)

    12/17/25 4:06:29 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SVP, CLO and Company Secretary Hutchinson Michael Damon converted options into 2,254 units of Ordinary Shares and covered exercise/tax liability with 1,122 units of Ordinary Shares, increasing direct ownership by 20% to 6,798 units (SEC Form 4)

    4 - LivaNova PLC (0001639691) (Issuer)

    12/17/25 4:06:15 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    SEC Filings

    View All

    SEC Form IRANNOTICE filed by LivaNova PLC

    IRANNOTICE - LivaNova PLC (0001639691) (Filer)

    2/25/26 3:32:08 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by LivaNova PLC

    10-K - LivaNova PLC (0001639691) (Filer)

    2/25/26 3:26:24 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LivaNova PLC (0001639691) (Filer)

    2/25/26 6:05:16 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Leadership Updates

    Live Leadership Updates

    View All

    LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. "Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector," Makatsaria said. "With her extensive OSA market expertise, she has a strong track record in creating new sleep therapy pathways, improving patient access to care, and building strong commercial teams. Her leadership will help us unlock transformational growth by co

    12/2/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Donald Zurbay as a New Director

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of Directors, effective today. Zurbay will serve on the Audit and Compliance Committee for the Board. "LivaNova is pleased to welcome Don to our Board of Directors," said William Kozy, Chair of the Board. "Over the course of 30 years, he has amassed expertise in finance, accounting, and strategy, much of which he honed while serving in leadership positions with global healthcare companies. His deep experience and knowledge will be welcome assets to the Board." Zurbay joins the LivaNova Board of Directors after a seven-year tenure at Patterson C

    9/4/25 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

    1/6/25 9:00:00 AM ET
    $ABT
    $BMY
    $IRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $LIVN
    Financials

    Live finance-specific insights

    View All

    LivaNova to Announce First-Quarter 2026 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 946097. A replay will be available on the

    3/25/26 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

    – Delivered double-digit reported and organic revenue growth and continued operating margin expansion for full-year 2025 – Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 – Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective Jan. 1, 2026, significantly reducing a known barrier to procedure penetration – Received U.S. Food and Drug Administration approval for cloud-based digital health platform LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology com

    2/25/26 6:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

    LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 901145. A

    1/20/26 9:00:00 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $LIVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LivaNova PLC

    SC 13G - LivaNova PLC (0001639691) (Subject)

    4/17/24 4:19:05 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    2/12/24 4:01:13 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by LivaNova PLC (Amendment)

    SC 13G/A - LivaNova PLC (0001639691) (Subject)

    1/23/24 11:52:27 AM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care